LONDON, Feb 4 (APM) - AbbVie's Humira (adalimumab) for autoimmune diseases was the world's biggest-selling drug in 2014 after Gilead's Sovaldi (sofosbuvir) failed to take the number one spot, figures show.
Gilead Sciences reported in a late Tuesday statement full-year results showing Sovaldi sold $1.7 billion in the fourth quarter and $10.28 billion in 2014. Late last month, AbbVie said Humira sold $3.4 billion over the last quarter of 2014 and $12.5 billion over the year. (APMMA 41298)
Harvoni, a recently-launched combination therapy in the U.S. for hepatitis C which includes Sovaldi, generated sales of $2.1 billion over the quarter, Gilead added. It was approved in Europe in November (APMMA 40487).
It said said fourth-quarter revenue soared to $7.3 billion from $3.1 billion, while net profit climbed from $791 million to $3.5 billion. For the full year, revenue was $24.9 billion, compared with $11.2 billion in 2013 and net profit accelerated from $3.1 billion to $12.1 billion.
However, Thomson Reuters reported Gilead executives saying on a conference call it is offering steeper-than-expected discounts on its hepatitis C drugs to health insurers and other group payers who had complained about the price, prompting a 5% slide in the share price.
Gilead, also the world's largest producer of branded HIV drugs, reported HIV combination pill Atripla generated $925 million, against $933 million on the previous year's quarter, while Truvada sales climbed to $897 million from $814 million in the same quarter in 2013.
Other combination HIV therapies Complera/Eviplera jumped to $348 million from $262 million and Stribild soared to $385 million compared with $204 million in the last quarter of 2013.
In the cardiovascular field, Ranexa climbed to $144 million from $130 million and Letairis grew from $139 million to $181 million.
nh/ns
TRY APM Market Access AND GET ACCESS TO THE FULL CONTENT
Interviews with KOLs/senior executives amongst the Regulators, Payers, Health, Medical & Pharmaceutical organisations
Events coverage with a unique focus on Market Access & sustainability of healthcare systems
6 European bureaus : Berlin, Brussels, London, Madrid, Milan & Paris
Ask for a Free trial and get access to the latest stories
Our coverage includes:
- Health Care
- Market Access
- HTA – policies & practices
- European medicine regulations
- Drug safety issues
- Pricing & Reimbursement
- International medicines agencies
If you are a Payer, Pharmaceutical or Consulting professional our premium data will keep you informed on the regulatory, pricing, market access and cost-effectiveness issues that impact all stakeholders.
REQUEST
an initial 10 day temporary access of APM Market Access.
